CARSGEN
Live / Registered — Registered (as of 09 Dec 2025)
What this means for you
Registered since 09 Dec 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79402612
- Registration number
- 8054675
- Mark type
- Word mark
- Filed
- 09 Apr 2024
- Published for opposition
- 21 Oct 2025
- Registered
- 09 Dec 2025
- Attorney of record
- Adam Bell
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological preparations for medical purposes for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; medicinal solutions for injection, namely, medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biomedicine for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; blood for medical purposes; pre-filled syringes for medical purposes filled with pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; pharmaceuticals for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological tissue cultures for medical purposes; serotherapeutic medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases
- Class 042 — Scientific and technological services: Scientific research; scientific laboratory services; research and development of new products for others; technical project studies, namely, conducting scientific feasibility studies; technological research in the field of pharmaceutical studies, biotechnology, medicine, immunotherapy; chemical research; chemistry services, namely, chemist services and chemistry consultation; chemical analysis; medical research; medical and scientific research, namely, conducting clinical trials for others; biological research
- Class 044 — Medical, beauty and agricultural services: Medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; human tissue bank services; alternative medicine services; therapy services, namely, medical therapy, medicine therapy, immunotherapy, cell therapy, gene therapy, antibody therapy, antibody-drug conjugate therapy, radiation therapy, chemotherapy, and stem cell therapy; telemedicine services; health care; medical clinic services
Owner
Prosecution history
- 09 Mar 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 05 Feb 2026 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 21 Jan 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 21 Jan 2026 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 09 Dec 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 09 Dec 2025 — REGISTERED-PRINCIPAL REGISTER
- 21 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Oct 2025 — PUBLISHED FOR OPPOSITION
- 15 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Sept 2025 — EXAMINER'S AMENDMENT ENTERED
- 23 Sept 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 23 Sept 2025 — EXAMINERS AMENDMENT E-MAILED
- 23 Sept 2025 — EXAMINERS AMENDMENT -WRITTEN
- 04 Apr 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED